Skip to main
BCPC
BCPC logo

Balchem (BCPC) Stock Forecast & Price Target

Balchem (BCPC) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Balchem Corp reported a top-line revenue of $255.5 million in 2Q25, which surpassed estimates and marked a 1% year-over-year increase, alongside a slight sequential growth from the previous quarter. The company's price-to-earnings (P/E) multiple increased to 39.6x, reflecting investor confidence, and forecasts suggest ongoing improvements in both gross and net margins. Furthermore, Balchem is projected to reach a debt-free status by the end of the next year, positioning the company favorably for potential accretive mergers and acquisitions due to the strength of its balance sheet.

Bears say

Balchem Corp faces several significant risks that contribute to a negative outlook on its stock, including slower-than-anticipated growth in its core business segments and ongoing inflationary pressures that could impact profitability. Additionally, the company's reliance on the successful launch of new nutrition products is a concern, particularly given the uncertainty surrounding FDA approval for its partner Curemark's autism drug candidate. Furthermore, potential disruptions to Balchem's European operations due to regional conflicts pose additional challenges that could adversely affect overall performance.

Balchem (BCPC) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Balchem (BCPC) Forecast

Analysts have given Balchem (BCPC) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Balchem (BCPC) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $189, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $189, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Balchem (BCPC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.